Quarterly Financial Data (Unaudited and restated) (Tables)

12 Months Ended

Dec. 31, 2022

Quarterly Financial Data (Unaudited and restated)

Schedule of Quarterly Financial Data (Unaudited and restated)

The restated consolidated balance sheet line items for the second through third fiscal quarters of 2022 are as follows:

	June 30, 2022
	As Previously Reported		Adjustments		As Restated		Reclass for Discontinued Operations		Revised
Deferred tax liability	$	3,541,937	$	(3,326,000)	$	215,937	$	—	$	215,937
Total Liabilities		36,467,130		(3,326,000)		33,141,130		—		33,141,130
Accumulated deficit		(183,996,826)		3,326,000		(180,670,826)		—		(180,670,826)
Total Stockholders' Equity - NightHawk Biosciences, Inc.		96,638,241		3,326,000		99,964,241		—		99,964,241
Total Stockholders' Equity	$	95,387,663	$	3,326,000	$	98,713,663	$	—	$	98,713,663

	September 30, 2022
	As Previously Reported		Adjustments		As Restated		Reclass for Discontinued Operations		Revised
Goodwill	$	3,467,747	$	(253,000)	$	3,214,747	$	(3,214,747)	$	—
Total Assets		120,164,913		(253,000)		119,911,913		—		119,911,913
Deferred tax liability		3,326,000		(3,326,000)		—		—		—
Total Liabilities		37,039,187		(3,326,000)		33,713,187		—		33,713,187
Accumulated deficit		(197,002,176)		3,073,000		(193,929,176)		—		(193,929,176)
Total Stockholders' Equity - NightHawk Biosciences, Inc.		84,465,725		3,073,000		87,538,725		—		87,538,725
Total Stockholders' Equity		83,125,726		3,073,000		86,198,726		—		86,198,726
Total Liabilities and Stockholders' Equity	$	120,164,913	$	(253,000)	$	119,911,913	$	—	$	119,911,913

The restated items of the consolidated statements of operations and comprehensive loss for the second through third fiscal quarters of 2022 are as follows:

	For the Three Months Ended June 30, 2022
	As Previously Reported		Adjustments		As Restated		Reclass for Discontinued Operations		Revised
Income tax benefit	$	—	$	3,326,000	$	3,326,000	$	(3,326,000)	$	—
Net loss from continuing operations		(10,263,910)		3,326,000		(6,937,910)		(2,095,160)		(9,033,070)
Net loss from discontinued operations before income taxes		—		—		—		(1,230,840)		(1,230,840)
Income tax benefit from discontinued operations		—		—		—		3,326,000		3,326,000
Net loss		(10,263,910)		3,326,000		(6,937,910)		—		(6,937,910)
Net loss attributable to NightHawk Biosciences, Inc.		(10,157,286)		3,326,000		(6,831,286)		—		(6,831,286)
Net loss per share, basic and diluted from continuing operations	$	(0.40)	$	0.13	$	(0.27)	$	(0.08)	$	(0.35)
Net loss per share, basic and diluted from discontinued operations	$	—	$	—	$	—	$	0.08	$	0.08
Total comprehensive loss		(10,114,055)		3,326,000		(6,788,055)		—		(6,788,055)
Comprehensive loss - NightHawk Biosciences, Inc.	$	(10,007,431)	$	3,326,000	$	(6,681,431)	$	—	$	(6,681,431)

	For the Six Months Ended June 30, 2022
	As Previously Reported		Adjustments		As Restated		Reclass for Discontinued Operations		Revised
Income tax benefit	$	-	$	3,326,000	$	3,326,000	$	(3,326,000)	$	—
Net loss from continuing operations		(18,453,708)		3,326,000		(15,127,708)		(2,095,160)		(17,222,868)
Net loss from discontinued operations before income taxes		—		—		—		(1,230,840)		(1,230,840)
Income tax benefit from discontinued operations		—		—		—		3,326,000		3,326,000
Net loss		(18,453,708)		3,326,000		(15,127,708)		—		(15,127,708)
Net loss attributable to NightHawk Biosciences, Inc.		(18,277,873)		3,326,000		(14,951,873)		—		(14,951,873)
Net loss per share, basic and diluted from continuing operations	$	(0.71)	$	0.13	$	(0.58)	$	(0.09)	$	(0.67)
Net loss per share, basic and diluted from discontinued operations	$	—	$	—	$	—	$	0.08	$	0.08
Total comprehensive loss		(18,359,122)		3,326,000		(15,033,122)		—		(15,033,122)
Comprehensive loss - NightHawk Biosciences, Inc.	$	(18,183,287)	$	3,326,000	$	(14,857,287)	$	—	$	(14,857,287)

	For the Three Months Ended September 30, 2022
	As Previously Reported		Adjustments		As Restated		Reclass for Discontinued Operations		Revised
Income tax benefit (expense)	$	215,937	$	(253,000)	$	(37,063)	$	253,000	$	215,937
Net loss from continuing operations		(13,094,771)		(253,000)		(13,347,771)		2,953,943		(10,393,828)
Net loss from discontinued operations before income taxes		—		—		—		(2,700,943)		(2,700,943)
Income tax benefit from discontinued operations		—		—		—		(253,000)		(253,000)
Net Loss		(13,094,771)		(253,000)		(13,347,771)		—		(13,347,771)
Net loss attributable to NightHawk Biosciences, Inc.		(13,005,350)		(253,000)		(13,258,350)		—		(13,258,350)
Net loss per share, basic and diluted - continuing operations	$	(0.51)	$	(0.01)	$	(0.52)	$	0.12	$	(0.40)
Net loss per share, basic and diluted - discontinued operations	$	—	$	—	$	—	$	(0.12)	$	(0.12)
Total comprehensive loss		(12,979,112)		(253,000)		(13,232,112)		—		(13,232,112)
Comprehensive loss - NightHawk Biosciences, Inc.	$	(12,889,691)	$	(253,000)	$	(13,142,691)	$	—	$	(13,142,691)

	For the Nine Months Ended September 30, 2022
	As Previously Reported		Adjustments		As Restated		Reclass for Discontinued Operations		Revised
Income tax benefit (expense)	$	215,937	$	3,073,000	$	3,288,937	$	(3,073,000)	$	215,937
Net loss from continuing operations		(31,548,479)		3,073,000		(28,475,479)		858,782		(27,616,697)
Net loss from discontinued operations before income taxes		—		—		—		(3,931,782)		(3,931,782)
Income tax benefit from discontinued operations		—		—		—		3,073,000		3,073,000
Net Loss		(31,548,479)		3,073,000		(28,475,479)		—		(28,475,479)
Net loss attributable to NightHawk Biosciences, Inc.		(31,283,223)		3,073,000		(28,210,223)		—		(28,210,223)
Net loss per share, basic and diluted - continuing operations	$	(1.22)	$	0.12	$	(1.10)	$	0.03	$	(1.07)
Net loss per share, basic and diluted - discontinued operations	$	—	$	—	$	—	$	(0.03)	$	(0.03)
Total comprehensive loss		(31,338,234)		3,073,000		(28,265,234)		—		(28,265,234)
Comprehensive loss - NightHawk Biosciences, Inc.	$	(31,072,978)	$	3,073,000	$	(27,999,978)	$	—	$	(27,999,978)

While the adjustments changed the deferred tax liability line item in the unaudited consolidated statements of cash flows, they did not have an impact on total net cash provided by operating activities, net cash used in investing activities, or net cash (used in) provided by financing activities for any of the applicable periods.

The restated line items of the unaudited consolidated statements of cash flows for the second through third fiscal quarters of 2022 are as follows:

	For the Six Months Ended,		For the Nine Months Ended,		For the Six Months Ended,		For the Nine Months Ended,		For the Six Months Ended,		For the Nine Months Ended,
	June 30, 2022		September 30, 2022		June 30, 2022		September 30, 2022		June 30, 2022		September 30, 2022
	As Previously Reported				Adjustments				As Restated
Net loss	$	(18,453,708)	$	(31,548,479)	$	3,326,000	$	3,073,000	$	(15,127,708)	$	(28,475,479)
Adjustments to reconcile net loss to net cash used in operating activities:
Deferred tax liability	$	—	$	(215,937)	$	(3,326,000)	$	(3,073,000)	$	(3,326,000)	$	(3,288,937)